Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors

• DOI: 10.1016/j.neo.2024.100974
• Publication Date: 2024-02-16T07:59:35Z
• Authors: Xiang Zhou; Rui He; Wei-Xin Hu; Saiqun Luo; Jingping Hu
• Keywords: 0303 health sciences; 03 medical and health sciences; Multiple myeloma; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Warburg effect; Review Article; Cancer metabolism; RC254-282

Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, cells have acquired functional capabilities which are referred to as "Hallmarks Cancer", and one their most important features the metabolic disorders. Due high secretory load MM cells, first-line medicine proteasome inhibitors found pronounced effects in for blocking degradation misfolded proteins, leading accumulation ER overwhelming stress. Moreover, been reported be effective by targeting glucose, lipid, amino acid metabolism cells. In this review, we described abnormal three major nutrients, such lipid acids, participate cellular functions. We roles progression, how they could exploited therapeutic purposes, current strategies these metabolites, hoping uncover potential novel targets promote development future approaches.